studies

mML - L1 - BRAF mutant, immune chekpoint inhibitors vs. anti-CTLA-4, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49] 1.44[0.46; 4.49]CheckMate 069 (BRAF mutant) EXPLORATORY, 201510%33NAnot evaluable PFS (extension)detailed resultsCheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27] 0.47[0.10; 2.27]CheckMate 069 (BRAF mutant) EXPLORATORY, 201510%33NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98] 0.38[0.15; 0.98]CheckMate 069 (BRAF mutant) EXPLORATORY, 201510%33NAnot evaluable objective responses (ORR)detailed resultsCheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91] 9.82[0.45; 212.91]CheckMate 069 (BRAF mutant) EXPLORATORY, 201510%33NAnot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42] 9.80[0.45; 211.42]CheckMate 069 (BRAF mutant) EXPLORATORY, 201510%33NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-10-05 07:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 127 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743